Publication: Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers.
dc.contributor.author | Gil-Gomez, Antonio | |
dc.contributor.author | Brescia, Paola | |
dc.contributor.author | Rescigno, Maria | |
dc.contributor.author | Romero-Gomez, Manuel | |
dc.date.accessioned | 2023-02-09T11:40:17Z | |
dc.date.available | 2023-02-09T11:40:17Z | |
dc.date.issued | 2021-03-08 | |
dc.description.abstract | Nonalcoholic fatty liver disease (NAFLD) is a systemic, dynamic, heterogeneous, and multiaxis entity, the pathogenesis of which is still uncertain. The gut-liver axis is regulated and stabilized by a complex network encompassing a metabolic, immune, and neuroendocrine cross-talk between the gut, the microbiota, and the liver. Changes in the gut-liver axis affect the metabolism of lipids and carbohydrates in the hepatocytes, and they impact the balance of inflammatory mediators and cause metabolic deregulation, promoting NAFLD and its progression to nonalcoholic steatohepatitis. Moreover, the microbiota and its metabolites can play direct and indirect roles in gut barrier function and fibrosis development. In this review, we will highlight findings from the recent literature focusing on the gut-liver axis and its relation to NAFLD. Finally, we will discuss the impact of technical issues, design bias, and other limitations on current knowledge of the gut microbiota in the context of NAFLD. | |
dc.description.version | No | |
dc.identifier.citation | Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Semin Liver Dis. 2021 May;41(2):191-205. | |
dc.identifier.doi | 10.1055/s-0041-1723752 | |
dc.identifier.essn | 1098-8971 | |
dc.identifier.pmid | 34107545 | |
dc.identifier.unpaywallURL | http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0041-1723752.pdf | |
dc.identifier.uri | http://hdl.handle.net/10668/17980 | |
dc.issue.number | 2 | |
dc.journal.title | Seminars in liver disease | |
dc.journal.titleabbreviation | Semin Liver Dis | |
dc.language.iso | en | |
dc.organization | Instituto de Biomedicina de Sevilla-IBIS | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.page.number | 191-205 | |
dc.provenance | Realizada la curación de contenido 18/02/2025 | |
dc.publisher | Thieme Medical Publishers, Inc. | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Research Support, Non-U.S. Gov't | |
dc.pubmedtype | Review | |
dc.relation.publisherversion | https://www.thieme-connect.com/DOI/DOI?10.1055/s-0041-1723752 | |
dc.rights.accessRights | Restricted Access | |
dc.subject | Microbiota | |
dc.subject | Microbiome | |
dc.subject | NAFLD | |
dc.subject | NASH | |
dc.subject | Gut–Liver axis | |
dc.subject.decs | Enfermedad del hígado graso no alcohólico | |
dc.subject.decs | Hígado | |
dc.subject.decs | Microbiota | |
dc.subject.decs | Volición | |
dc.subject.decs | Microbioma gastrointestinal | |
dc.subject.decs | Lípidos | |
dc.subject.decs | Conocimiento | |
dc.subject.decs | Hepatocitos | |
dc.subject.decs | Fibrosis | |
dc.subject.mesh | Gastrointestinal Microbiome | |
dc.subject.mesh | Hepatocytes | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Metagenome | |
dc.subject.mesh | Non-alcoholic Fatty Liver Disease | |
dc.title | Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 41 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- RISalud_Accesorestringido.pdf
- Size:
- 93.39 KB
- Format:
- Adobe Portable Document Format